Alaunos Therapeutics, Inc. Cash Flow Statement
TCRT|11 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 11 fiscal years. All figures from audited SEC 10-K filings.
Alaunos Therapeutics, Inc. used $5M in operating cash flow and negative free cash flow of $5M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.79 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$4.7M | -$35.1M | -$37.7M | -$78.8M | -$80.0M | -$53.1M | -$54.3M | -$165.3M | -$5.7M | -$160.0K | -$160.0K |
| Depreciation & Amortization | $2.0K | $2.3M | $2.8M | $2.6M | $1.1M | $575.0K | $369.0K | $290.0K | $268.0K | $188.0K | $330.0K |
| Operating Cash Flow | -$5.0M | -$30.1M | -$29.2M | -$61.5M | -$57.0M | -$49.5M | -$54.7M | -$58.3M | -$38.8M | -$19.7M | -$12.3M |
| Capital Expenditures | $0 | $197.0K | $216.0K | $3.3M | $9.8M | $459.0K | $737.0K | $551.0K | $1.2M | $186.0K | $11.0K |
| Free Cash Flow | -$5.0M | -$30.3M | -$29.4M | -$64.8M | -$66.8M | -$49.9M | -$55.4M | -$58.9M | -$40.0M | -$19.9M | -$12.3M |
| Share Buybacks | - | - | $45.0K | $0 | - | $1.6M | $0 | $2.0K | $274.0K | $1.7M | $380.0K |
| FCF Margin | -49710.0% | -606780.0% | -1007.8% | -16279.2% | - | -34189.0% | -348.5% | -370.3% | - | -2980.5% | -1844.8% |